Vigil Neuroscience, Inc.

NasdaqGS:VIGL Stock Report

Market Cap: US$74.7m

Vigil Neuroscience Management

Management criteria checks 2/4

Vigil Neuroscience's CEO is Ivana Magovcevic-Liebisch, appointed in Jul 2020, has a tenure of 4.5 years. total yearly compensation is $3.85M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $407.52K. The average tenure of the management team and the board of directors is 3 years and 3.8 years respectively.

Key information

Ivana Magovcevic-Liebisch

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage15.2%
CEO tenure4.5yrs
CEO ownership0.5%
Management average tenure3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Vigil Neuroscience: Down On A Competitor's Failure

Dec 03

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30
We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Sep 16

Vigil Neuroscience announces $75M PIPE financing

Aug 12

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Jul 25
We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Apr 10
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Ivana Magovcevic-Liebisch's remuneration changed compared to Vigil Neuroscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$84m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$4mUS$585k

-US$83m

Sep 30 2023n/an/a

-US$79m

Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$4mUS$557k

-US$68m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$3mUS$450k

-US$43m

Dec 31 2020US$3mUS$204k

-US$57m

Compensation vs Market: Ivana's total compensation ($USD3.85M) is above average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Ivana's compensation has increased whilst the company is unprofitable.

CEO

Ivana Magovcevic-Liebisch (57 yo)

4.5yrs

Tenure

US$3,847,287

Compensation

Dr. Ivana Magovcevic-Liebisch, Ph. D., J. D., serves as a Director of Quanterix Corporation since October 2024. She serves as an Independent Director of Acrivon Therapeutics, Inc. since February 08, 2024....

Leadership Team

NamePositionTenureCompensationOwnership
Ivana Magovcevic-Liebisch
President4.5yrsUS$3.85m0.55%
$ 407.5k
Jennifer Ziolkowski
Chief Financial Officer3.8yrsUS$1.70m0.0098%
$ 7.3k
David Gray
Chief Scientific Officer1.9yrsUS$2.77m0%
$ 0
Sharon Morani
Senior Director of Facilities & Operations2yrsno datano data
Eric Brophy
Senior Manager of Information Technologyno datano datano data
Leah Gibson
Vice President of Investor Relations and Corporate Communicationsno datano datano data
April Effort
VP & Head of Corporate Development3yrsno datano data
Evan Thackaberry
Senior VP & Head of Early Development4.3yrsno data0.0037%
$ 2.7k
Christian Mirescu
Senior VP & Head of Neuroimmunology3yrsno datano data
Weeteck Yeo
Senior Vice President of Strategic Operations3yrsno datano data
Jessica Stromme
Senior Vice President of Program Leadership & Portfolio Management3yrsno datano data
Ali Toumadj
VP & Head of Medical Sciences2yrsno datano data

3.0yrs

Average Tenure

50yo

Average Age

Experienced Management: VIGL's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ivana Magovcevic-Liebisch
President4.5yrsUS$3.85m0.55%
$ 407.5k
Suzanne Bruhn
Independent Director2.5yrsUS$138.50k0%
$ 0
Cheryl Blanchard
Independent Director4.2yrsUS$140.00k0%
$ 0
Mary Thistle
Independent Director2.8yrsUS$143.83k0%
$ 0
Ole Isacson
Member of Scientific Advisory Board3yrsno datano data
Bruce Booth
Independent Chairman of the Board4.6yrsUS$165.00k0%
$ 0
Marco Colonna
Chairman of Scientific Advisory Boardno datano datano data
Gerhard Koenig
Independent Director4.5yrsUS$136.33k0%
$ 0
Bradley Hyman
Member of Scientific Advisory Boardno datano datano data
Stefan Vitorovic
Independent Director3.4yrsUS$136.83k0.064%
$ 47.7k
Jaime Grutzendler
Member of Scientific Advisory Boardno datano datano data
John Dunlop
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: VIGL's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 21:55
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vigil Neuroscience, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yatin SunejaGuggenheim Securities, LLC
Andrew FeinH.C. Wainwright & Co.
Lin TsaiJefferies LLC